Functionally, Ythdf1 knockout or inhibition via LNP-siRNA significantly potentiates anti–PD-1 therapy, identifying YTHDF1 as a promising therapeutic target in NASH-HCC (18). Here, YTHDF1 is linked to hepatocellular carcinoma.